|MDACC Study No:||2013-0873 (clinicaltrials.gov NCT No: NCT01993641)|
|Title:||A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients with Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone|
|Principal Investigator:||Guillermo Garcia-Manero|
|Treatment Agent:||Azacitidine; Decitabine; Pracinostat|
|Study Description:||The goal of this clinical research study is to learn if adding pracinostat to |
the drug that you have already received (azacitidine or decitabine) can help to
control MDS. The safety of this drug combination will also be studied.
The main part of the study has completed. However, an extension phase has been
added to this study to allow patients already receiving pracinostat to continue
to receive pracinostat if they/their study doctor feel they are benefitting
from treatment with pracinostat + azacitidine or decitabine. You are being
invited to take part in this extension phase.